Sucutaneous anifrolumab? Phase III TULIP-SC trial in SLE patients showed SC anifrolumab (Saphnelo) significantly reducted lupus disease activity compared to placebo. https://t.co/vvI2av2vAJ https://t.co/0V1wsmFk0N
Links:
Saphnelo self-administration TULIP-SC Phase III trial meets primary endpoint in…
https://buff.ly/meaC7fM
22-09-2025
